Over 1.5 million new cases of non-small cell lung cancer (NSCLC), a highly aggressive disease, are registered worldwide every year (1). Until the 1980s, treatment generally yielded poor outcomes (2), and prognosis was only good for early stages of operable disease. However, advances in targeted molecular therapy since 2005 have brought new hope to patients with advanced NSCLC, especially those harboring the *epidermal growth factor receptor* (*EGFR*) mutation in exons 18, 19 and 21 (3). As a result, the median overall survival (OS) of a small group of patients with advanced NSCLC increased from 10 to 18–36 months (2).

The fusion of the *EML4* gene (echinoderm microtubule-associated protein-like 4) and the *ALK* gene (anaplastic lymphoma kinase) affects the outcome of almost 5% of patients with this phenotype (2,4). Indeed, patients with this profile presented a very good overall response rate (74%) when submitted to treatment with crizotinib (an *ALK*-inhibitor) in the clinical trial PROFILE 1014 (5).

More recently, resistance mechanisms to *EGFR* and *ALK* inhibitors have raised concerns regarding disease progression. However, the use of checkpoint inhibitors targeting the mechanisms of CTLA4 (cytotoxic T-lymphocyte-associated protein 4) and PD1/PDL1 (programmed cell death protein 1 and ligand) has become a cornerstone in the treatment of NSCLC (6,7). Several drugs (e.g., ipilimumab, pembrolizumab and nivolumab) have been shown to be efficient and safe in the treatment of advanced NSCLC, though their mechanisms are still not fully understood (7,8). Quoix et al. recently published promising results from phase 2b/3 TIME trial (9). TG4010 is a modified vaccinia Ankara expressing MUC1 and interleukin 2. In addition, baseline levels of CD16, CD56 and CD69 (triple-positive activated lymphocytes; TrPAL) were measured to evaluate their potential as predictive biomarkers. The authors recruited 222 previously untreated stage IV NSCLC patients without a known activating *EGFR* mutation and with MUC1 expression in at least 50% of tumor cells, stratified them according to baseline TrPAL levels and allocated them to two groups (TG4010 + chemotherapy vs. placebo + chemotherapy) of 111 patients each. Progression-free survival (PFS) was longer in the former than in the latter (5.9 vs. 5.1 months, P=0.019), but overall survival (OS) was statistically similar in the two groups (12.7 vs. 10.6 months, respectively; P=0.055).

In patients with non-squamous histology and TrPAL levels below the upper limit of normal (ULN), survival was longer when TG4010 was administered (PFS: 6.0 vs. 4.9 months, P=0.0033; OS: 15.1 vs. 10.3 months, P=0.0072). No significant difference was observed between the groups with regard to PDL1 levels, but patients in the TG4010 group experienced more grade 1 and 2 adverse events (fatigue: 51% vs. 47%; nausea: 46% vs. 40%; injection site reaction: 33% vs. 4%; dyspnea: 23% vs. 8%). Thus, in clinical practice premedication should be combined with appropriate anti-emetics, anti-histaminics and steroids to minimize adverse reactions and increase tolerability.
Considering the good results of this trial for patients with non-squamous histology and TrPAL levels below ULN, TG4010 appears to be a promising alternative to extend OS in the first-line setting for patients without the EGFR mutation or ALK fusion. In addition, nivolumab and pembrolizumab showed activity against advanced NSCLC in a second line setting; however a strong biomarker (PDL1 expression) unfortunately was not validated to this setting, providing a lack of efficacy information for those approaches. As for toxicity, the potential adverse effects of these new drugs require further study to ensure tolerability and quality of life. The validation of TrPAL levels as a new biomarker is urgently needed to tailor therapy for NSCLC patients and may represent the beginning of a new era in immunotherapy for NSCLC.

**Acknowledgements**

None.

**Footnote**

_Provenance:_ This is a Guest Commentary commissioned by Section Editor Jianrong Zhang, MD (Department of Thoracic Surgery, First Affiliated Hospital of Guangzhou Medical University, Guangzhou Institute of Respiratory Disease, Guangzhou, China).

_Conflicts of Interest:_ RA de Mello received advisory board honoraria from Pfizer, support from the National Science Center in Krakow (Poland), and educational grants from Pierre Fabre, Merck and Amgem. RAM is an _ad hoc_ consultant for the Brazilian Ministry of Health in Brasília.


**References**